Johnson & Johnson (NYSE: JNJ) eyes $5.5B ovarian talc settlement
Rhea-AI Filing Summary
Johnson & Johnson has agreed in principle to a comprehensive resolution of remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state cases. The proposed framework is conditioned on participation from at least 95% of remaining claimants, covering approximately 76,000 ovarian talc claims. It provides per-claim payments under a total $5.5 billion commitment, with a first payment of no more than $3 billion in 2027 and no additional payments due before 2028.
The company links this proposal to a recent MDL court ruling on “specific causation,” after which plaintiffs withdrew certain experts and the court ordered them to show why remaining claims should not be dismissed. Johnson & Johnson states it has already resolved about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes, and that this agreement, if completed, would efficiently conclude 15 years of talc litigation so it can focus on its Innovative Medicine and MedTech businesses.
Positive
- Proposed resolution of roughly 76,000 ovarian talc claims could significantly reduce legal uncertainty and future trial expenses if the 95% participation threshold and other conditions are satisfied.
Negative
- $5.5 billion talc litigation payment commitment represents a substantial future cash outflow, including up to $3 billion scheduled for 2027 under the proposed framework.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Settlement commitment: $5.5 billion
Initial payment cap: $3 billion
Participation threshold: 95% of remaining claims
+2 more
5 metrics
Settlement commitment
$5.5 billion
Overall commitment under proposed ovarian talc litigation resolution
Initial payment cap
$3 billion
Maximum first payment due in 2027 under the proposed framework
Participation threshold
95% of remaining claims
Minimum claimant participation required for the resolution to proceed
Remaining ovarian talc claims
76,000 claims
Claims the company indicates would be addressed by the proposal
Mesothelioma suits settled
about 95% of filed lawsuits
Portion of mesothelioma cases Johnson & Johnson reports as previously resolved
Key Terms
Multi-District Litigation (MDL), specific causation, bellwether cases, forward-looking statements, +1 more
5 terms
Multi-District Litigation (MDL) regulatory
"plaintiff firms leading the federal Multi-District Litigation (MDL) and related state"
specific causation medical
"prove that the Company’s talc products caused any particular claimant’s ovarian cancer (“specific causation”)"
bellwether cases regulatory
"withdrawing their experts on the topic in two bellwether cases."
forward-looking statements regulatory
"This press release contains “forward-looking statements” as defined in the Private"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Johnson & Johnson (JNJ) announce about its ovarian talc litigation?
Johnson & Johnson announced a proposed comprehensive resolution of remaining ovarian talc litigation, covering about 76,000 claims. The framework is subject to conditions, including a 95% participation threshold among remaining claimants in federal MDL and related state court cases.
How much could Johnson & Johnson (JNJ) pay under the proposed talc settlement?
The company agreed to a total commitment of $5.5 billion in per-claim payments. The first payment, capped at $3 billion, would be made in 2027, with no additional payments required before 2028 under the proposal.
What conditions must be met for Johnson & Johnson’s (JNJ) talc resolution to proceed?
The resolution requires, among other criteria, the express participation of at least 95% of remaining ovarian talc claimants. It also depends on participation by lead plaintiff firms in all pending state and federal ovarian talc litigation.
How many ovarian talc claims would the Johnson & Johnson (JNJ) proposal address?
The company states the proposed resolution would efficiently conclude litigation related to approximately 76,000 remaining ovarian talc claims. It says this would eliminate expenses associated with litigating those cases individually across federal and state courts.
How does this talc proposal relate to Johnson & Johnson’s (JNJ) prior settlements?
Johnson & Johnson reports it has already settled about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes. The new framework is presented as a step to conclude the remaining ovarian talc litigation.
Does the Johnson & Johnson (JNJ) talc resolution affect Kenvue’s liabilities?
The company reiterates that, prior to its consumer health separation, it agreed to retain all talc-related liabilities and indemnify Kenvue for litigation costs in the United States and Canada. The proposed resolution is consistent with that allocation of responsibility.
What is Johnson & Johnson’s (JNJ) position on the safety of its talc products?
Johnson & Johnson states that studies show talc is safe, does not contain asbestos, and does not cause cancer. It cites decades of research and regulatory reviews and characterizes the ovarian talc claims as lacking scientific merit, while including standard forward-looking and litigation risk disclosures.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 7.01 Regulation FD Disclosure
On July 27, 2026, the Company announced that it has reached an agreement for a comprehensive resolution of the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned upon, among other things, the express participation of at least of 95% of the remaining claims. The agreement calls for per claim payments, with a $5.5 billion commitment by the Company, and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028. The press release further discussing this announcement is attached below as Exhibit 99.1.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |||||||
99.1 | Press Release dated July 27, 2026 | |||||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | |||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 27, 2026
| JOHNSON & JOHNSON | |||||
(Registrant) | |||||
By: | /s/ Marc Larkins | ||||
Marc Larkins Corporate Secretary | |||||
Exhibit 99.1
 | Media contact: media-relations@its.jnj.com | Investor contact: investor-relations@its.jnj.com | ||||||
FOR RELEASE AT 6:15PM ET
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case
Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining 76,000 Ovarian Talc Claims
New Brunswick, N.J. – JULY 27, 2026 – Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowledgment by plaintiffs’ counsel, regarding plaintiffs’ inability to prove that the Company’s talc products caused any particular claimant’s ovarian cancer (“specific causation”).
“After decades of litigation and full vetting of the science in an extensive hearing, plaintiffs effectively conceded their inability to prove specific causation by withdrawing their experts on the topic in two bellwether cases. In a watershed moment, the Court thereafter ordered plaintiffs to show why the remaining claims should not be dismissed, confirming what we have maintained for years: that these claims lack scientific merit and were sustained only by unreliable expert opinions that could not survive rigorous judicial review," said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson. "The Court’s order placed plaintiffs in an untenable position of having to present specific causation evidence to maintain their claims that does not exist. While we are confident the Company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the Company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives."
The MDL Court’s recent specific causation ruling confirmed the Company's longstanding position that these claims lack scientific merit.
•The Company has prevailed in the overwhelming majority of ovarian cases tried to date.
•On July 22, 2026, the MDL court ordered plaintiffs to show why the remaining pending talc claims should not be dismissed for inability to prove specific causation.
•The order followed plaintiffs’ withdrawal of their specific causation experts in two bellwether cases, after a hearing that demonstrated their opinions were not based upon reliable scientific methodologies.
•The developments affirmed the Company’s longstanding position that the talc claims are premised on junk science that has been rejected for decades by United States scientific organizations and regulatory agencies, as well as independent experts.
The proposed resolution constitutes an efficient conclusion to the talc litigation.
The resolution:
•Requires and is conditioned on—among other criteria—the participation of lead plaintiff firms in all ovarian talc litigation pending in state and federal court, representing at least 95% of the remaining claims.
•Calls for per claim payments, with a $5.5 billion commitment by the Company and the first payment of no more than $3 billion to be made in 2027 and no additional payments due before 2028.
•Complements the progress the Company already has made to resolve the talc litigation, including previously settling about 95% of filed mesothelioma lawsuits, all State consumer protection claims, and all talc-supplier disputes.
•Brings finality to this meritless 15-year litigation.
Studies show talc is safe, does not contain asbestos and does not cause cancer.
•Research, clinical evidence, and decades of studies by independent medical experts around the world continue to support the safety of cosmetic talc.
•Prior to its separation, Johnson & Johnson agreed to retain all the talc-related liabilities and indemnify Kenvue for any and all costs—arising from litigation in the United States and Canada.
•As part of a worldwide portfolio assessment, Johnson & Johnson made the commercial decision to discontinue talc-based JOHNSON’S® Baby Powder globally in 2023. Additionally, Johnson & Johnson separated its consumer health business, Kenvue, in August 2023.
•Additional information on the Company's position and the science supporting the safety of talc is available at www.FactsAboutTalc.com.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the proposed resolution of ovarian talc litigation. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. Due to the inherent uncertainty of litigation, the Company cannot predict the timing, ultimate outcome or financial impact of this matter, or any other ongoing or future litigation. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: significant adverse litigation or government action, including related to product liability claims; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.